Conclusion


We know that Bergk1 has a high bioavailability of the alpha-linolenic acid it contains for humans. The alpha-linolenic acid is absorbed into the cells and there, as needed, is converted into DHA and EPA, into so-called Pufas.

We know that Bergk1 reduces the TNF-alpha (Tumor Necrotic Factory) by 60%. Since bergk1 does this in humans, Bergk1 will also show the required effects as published in the studies and weaken the power of the viruses. We are convinced of that

The studies on alpha linolenic acid and our experience with bergk1 lead to the conclusion that bergk1 must be used against covid19.